Alvesco + Omnaris + Qvar + Beconase-West Penn Allegheny Health System-asthma-allergic rhinitis

Alvesco + Omnaris + Qvar + Beconase-West Penn Allegheny Health System-asthma-allergic rhinitis refers to a clinical trial protocol (NCT00712101) that compared the safety and efficacy of two corticosteroid treatment regimens in pediatric patients. The study evaluated a ciclesonide-based regimen (Alvesco inhalation aerosol and Omnaris nasal spray) against a beclomethasone dipropionate-based regimen (Qvar inhalation aerosol and Beconase AQ nasal spray). Both ciclesonide and beclomethasone are synthetic glucocorticoids that act as agonists of the glucocorticoid receptor, providing anti-inflammatory effects for the management of asthma and allergic rhinitis. The primary focus of this specific study was to compare the impact of these combined inhaled and intranasal therapies on short-term lower leg growth in children, using knemometry as a sensitive measure of systemic corticosteroid activity and potential growth suppression.

Brand names

Beconase AQ

Other names

Ciclesonide vs Beclomethasone Growth StudyEffect of Ciclesonide vs Beclomethasone on Growth in Pediatric Asthma and Rhinitis